XMT-2056

Generic Name: XMT-2056

Drug Type: Biotech

Overview

XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.

Background

XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

FDA Grants Fast Track Designation to Mersana's Emiltatug Ledadotin for Expanded Breast Cancer Treatment

4 months ago

The FDA has granted Fast Track designation to Mersana's Emiltatug Ledadotin (XMT-1660) for advanced or metastatic HER2-low or HER2-negative breast cancer, including triple-negative breast cancer.

Emiltatug Ledadotin (XMT-1660) Shows Promise in Phase 1 Trial, Receives FDA Fast Track for Advanced Breast Cancer

4 months ago

Mersana Therapeutics' Emiltatug Ledadotin (XMT-1660) demonstrates a favorable safety profile in a Phase 1 trial with no Grade 4 or 5 treatment-related adverse events.

Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments

5 months ago

Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions.

Merus' Petosemtamab and Mersana's Emi-Le Show Promise in Cancer Treatment

6 months ago

Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months.

FDA Grants Fast Track Designation to Mersana Therapeutics' XMT-1660 for Triple-Negative Breast Cancer Treatment

3 years ago

Mersana Therapeutics, Inc. announced that the FDA has granted Fast Track designation to XMT-1660, a novel treatment for adult patients with advanced or metastatic triple-negative breast cancer (TNBC). This designation aims to expedite the development and review of XMT-1660, which has shown promising anti-tumor effects in preclinical studies.

Drug Development Updates